Constructs | Amino Acid Changes | Protein |
---|---|---|
fmol/mg | ||
β1-WT | 556 ± 39 | |
β1-TM1 | L63I, L64V, A66S, L71A, A74F, V81T | 372 ± 47 |
β1-TM2 | M98T, S102C, L110A, T117A, I118H, V119I, V120L | 567 ± 58 |
β1-TM3 | L133F, V137I, L154V | 1994 ± 214 |
β1-TM4 | G177V, L178I, V179I, C180L, T181M, A184I, I185V, A187G, V189T, L195Q, W199Y | 233 ± 18 |
β1-TM5 | R222Q, V230I, C238V, A241V, L245S | 359 ± 30 |
β1-TM6 | V332T, L342I, A343V, V345I, K347H, A348V, F349I | 1207 ± 100 |
β1-TM7 | R357E, L358V, F359Y, V360I, F361L, F362L, L365I, A368V, A371G, I375L | 2078 ± 133 |
β1-A187G | A187G | |
β1-V189T | V189T | |
β1-L195Q | L195Q | |
β1-W199Y | W199Y | |
β1-TM4 stage 1 | G177V, L178I, V179I | |
β1-TM4 stage 2 | G177V, L178I, V179I, C180L, T181M, A184I, I185V | |
β1-TM4 stage 3 | G177V, L178I, V179I, C180L, T181M, A184I, I185V, A187G | |
β1-TM4 stage 4 | G177V, L178I, V179I, C180L, T181M, A184I, I185V, A187G, V189T | |
β1-TM4 stage 5 | G177V, L178I, V179I, C180L, T181M, A184I, I185V, A187G, V189T, L195Q | |
β1-V189T-L195Q | V189T, L195Q | |
β1-V189T-W199Y | V189T, W199Y | |
β1-L195Q-W199Y | L195Q, W199Y | |
β1-V189T-L195Q-W199Y | V189T, L195Q, W199Y | |
β1-W199A | W199A | |
β1-W199D | W199D | |
β1-W199F | W199F | |
β1-W199K | W199K | |
β1-W199L | W199L | |
β1-W199N | W199N | |
β2-WT | 268 ± 25 | |
β2-TM1 | I38L, V39L, S41A, A46L, F49A, T56V | 138 ± 8 |
β2-TM2 | T73M, C77S, A85L, A92T, H93I, I94V, L95V | 405 ± 41 |
β2-TM3 | F108L, I112V, V129L | 1037 ± 113 |
β2-TM4a | V152G, I153L, I154V, L155C, M156T, I159A, V160I, G162A, T164V, Q170L | 458 ± 64 |
β2-TM5 | Q197R, I205V, V213C, V216A, S220L | 849 ± 83 |
β2-TM6 | T281V, I291L, V292A, I294V, H296K, V297A, I298F | 728 ± 58 |
β2-TM7 | E306R, V307L, Y308F, I309V, L310F, L311F, I314L, V317A, G320A, L324I | 67 ± 5 |
↵a Making the full change here (i.e., with Y174W) rendered the receptor nonfunctional (no binding and no functional responses). This chimera with 10 of the 11 amino acid substitutions was therefore used as the β2-TM4 mutant.